Clinical Trial

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks

Study acronym: PRO-ACTIVE
Recruiting
View on ClinicalTrials.gov →
Summary
The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase. The PRO-ACTIVE study includes the following activities: * WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors * WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences * WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors * WP4: Study of the tumor microenvironment for recurrence prediction
Trial Details
NCT Number NCT07469709
Lead Sponsor Fondazione del Piemonte per l'Oncologia
Conditions Breast Cancer, Colo-rectal Cancer, Ovarian Cancer, Melanoma (Skin Cancer), Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)
Enrollment 850 participants
Start Date 2024-02-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13